Vaxcyte (PCVX) Other Operating Expenses (2022 - 2023)
Vaxcyte (PCVX) posted quarterly Other Operating Expenses of $75.0 million for Q4 2023, up 226.16% year-over-year from $23.0 million in Q4 2022, and up 226.16% quarter-over-quarter from $23.0 million in Q4 2022.
Powered by 
Analysis
Vaxcyte (PCVX) Other Operating Expenses (2022 - 2023) Analysis & Trends
Vaxcyte (PCVX) has reported Other Operating Expenses for 2 consecutive years, with $75.0 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Other Operating Expenses rose 226.16% year-over-year to $75.0 million; the TTM figure through Sep 2024 stood at $75.0 million (up 226.16% YoY), while the FY2022 annual figure was -$44000.0, changed N/A from the prior year.
- Other Operating Expenses climbed to $75.0 million in Q4 2023 per PCVX's latest filing, from $23.0 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $75.0 million in Q4 2023 and bottomed at $23.0 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Vaxcyte | 8.83 Bn | 8.83 Bn | - |